echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The world's best-selling third-place variety, the local three males compete for food! Shuanglu, Zhengda Tianqing, Qilu, who is the strongest?

    The world's best-selling third-place variety, the local three males compete for food! Shuanglu, Zhengda Tianqing, Qilu, who is the strongest?

    • Last Update: 2019-06-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Lenalidomide is the core drug for the treatment of multiple myeloma It is recommended as a kind of treatment drug by the related guidelines of multiple myeloma at home and abroad At present, with the further promotion of the consistency evaluation of domestic generic drugs and the volume procurement, the bid winning enterprises have successively obtained substantial benefits Renadulamine generic drugs of local enterprises are listed one after another, and the drug will gradually realize localization In the future, the competition in China's generic drug market will be more fierce, and high-quality generic drugs will become the main force of the market Among the top 10 best-selling drugs in the world in 2018, the leader in the field of oncology medicine ranked the third in the list, with an increase of 18.3% over the same period In 2018, among the top 10 anti-tumor drugs in the world, lenalidomide of new group ranked first According to the prediction of professionals, lenalidomide will continue to maintain a rapid growth momentum in the next few years In 2019, the global sales of lenalidomide is predicted to be $10.9 billion, which is still the leader in the field of cancer In 2005, the global sales volume of new base's lenalidomide was only US $03 million, US $500 million in 2007, US $1 billion in 2008, US $2 billion in 2010, US $3 billion in 2012, US $4 billion in 2013, US $5 billion in 2014, US $6 billion in 2015, US $7 billion in 2016, US $8 billion in 2017, and US $10 billion in 2018 Yuan One big step a year, the growth can be described as rapid According to Xinji's financial report for the first quarter of 2019, the sales volume of lenalidomide was US $2577 million, up 15% year on year Figure 1: Sales of naduramide (in millions of US dollars) in the years of 2006-2018 The global growth rate of naduramide was a little fierce The original research drug was developed by new base, and was approved by FDA in December 2005, with the trade name of "revimid" It was approved by EMA in June 2007, and approved by PMDA in Japan on June 25, 2010 In 2018, lenalidomide capsules ranked the top 10 best-selling anti-tumor drugs with sales volume of US $9.685 billion In recent years, naduramine's global sales volume has maintained double-digit growth, with huge market potential In January 2013, the new lenalidomide was approved to enter China, with the trade name of "rifume" The dosage form is capsule, with the specifications of 5mg, 10mg, 15mg and 25mg According to the data of domestic sample hospitals, in 2018, the terminal sales of lenalidomide hospital was 142 million yuan, an increase of 547.3% over the previous year, with a rapid growth At present, in addition to the products of Xinji, the original manufacturer, there are also products of Shuanglu pharmaceutical, Zhengda Tianqing and Qilu pharmaceutical to compete in the domestic market Among them, lenalidomide of Beijing Shuanglu Pharmaceutical Co., Ltd is declared and approved for production according to new drug category 3.1 and products of Zhengda Tianqing Pharmaceutical Co., Ltd according to generic drug category 6 It still needs to pass the consistency evaluation At present, both enterprises have submitted supplementary applications for consistency evaluation On April 25, linadulamine capsule of Qilu pharmaceutical was approved by the State Food and Drug Administration for listing The product was listed in four categories of generic drugs, and it was deemed to have passed the consistency evaluation after being approved for production This is another heavyweight blood system anti-tumor drug approved by Qilu pharmaceutical after the introduction of bortezomib for injection in 2017 Qilu Pharmaceutical Co., Ltd has become a domestic enterprise with two major myeloma drugs The compound patent of local enterprise Sanxiong to compete for lenalidomide expired in July 2017 At present, in addition to the product listing of original research enterprise Xinji and three local enterprises Shuanglu, Zhengda Tianqing and Qilu pharmaceutical, there are many domestic enterprises accelerating the layout In November 2017, lenalidomide capsules of Shuanglu Pharmaceutical Co., Ltd won the first imitated listing in China; in January 2019, Zhengda Tianqing came to the second imitated listing of lenalidomide capsules Qilu Pharmaceutical Co., Ltd is the third enterprise approved to be listed in naduandiamine, but it is the first one that has been evaluated, and will occupy an advantageous position in the next bidding procurement According to the drug use data of domestic sample hospitals, the amount of naduramine used in 2013 was 1.75 million yuan, 10.78 million yuan in 2014, 13.56 million yuan in 2015, 19.21 million yuan in 2016, 22.02 million yuan in 2017 and 143 million yuan in 2018 In the past five years of domestic listing, the sales growth of the drug is not very fast, but in 2018, the growth is rapid Analysis of the reasons, the previous growth rate is not fast, mainly due to the high price of imported drugs, in the domestic market some acclimatized However, after the product entered the medical insurance catalog, the market changed a lot in 2018 Figure 22013-2018 market situation of lenalidomide sample hospital in China (unit: 10000 yuan) on July 19, 2017, 36 kinds of negotiation drugs, such as lenalidomide, were included in the category B scope of national basic medical insurance, industrial injury insurance and maternity insurance drug catalogue (2017 version) After August 2018, many countries have adjusted the prices of anticancer drugs negotiated by some early stage countries The medical insurance payment prices of lenalidomide 10mg and 25mg are respectively 811 yuan / pill and 1030 yuan / pill After the product entered the medical insurance catalog, the original research products reduced price, and the impact of generic drugs on the original research products, the market began to have a good performance in 2018 Original editor Feng Cuiyun: promise that this article is reprinted by yaozhi.com The copyright belongs to the original author The purpose of reprint is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.